-

XiFin Applauds House Ways and Means Committee Advancement of the Main Street Pharmacy Access Act

Healthcare technology leader urges Congress to pass bipartisan legislation securing senior access to pharmacist-delivered clinical services

SAN DIEGO--(BUSINESS WIRE)--XiFin, Inc., a leader in AI-driven revenue cycle management solutions and a business partner to more than half of pharmacies across the United States, today expressed strong support for H.R. 3164, the Main Street Pharmacy Access Act, which was advanced by the full House Ways and Means Committee after mark-up. The legislation has earned broad, bipartisan support, with more than 100 Congressional co-sponsors and the support of major healthcare organizations. XiFin joins other advocates in urging Congress to advance the legislation.

“XiFin is encouraged that the House Ways and Means Committee yesterday moved to advance the Main Street Pharmacy Access Act," said David Pope, PharmD, Chief Pharmacy Officer at XiFin.

Share

The Main Street Pharmacy Access Act ensures that America’s seniors have the same access as other healthcare consumers to essential pharmacist services, including testing and treatment for common respiratory illnesses, such as flu, strep throat, and RSV.

Medicare beneficiaries currently are not eligible for reimbursement for these and other pharmacist-provided clinical services already authorized by state laws. By addressing this gap, the Main Street Pharmacy Access Act would improve access to timely care for seniors and support the financial sustainability of community pharmacies.

“XiFin is encouraged that the House Ways and Means Committee yesterday moved to advance the Main Street Pharmacy Access Act. This legislation is particularly critical for seniors in rural and underserved areas, where pharmacies fill an important care gap. By reimbursing for these services, the legislation secures access for seniors and provides financial support for pharmacies so that they can continue to operate and serve their communities,” said David Pope, PharmD, Chief Pharmacy Officer at XiFin.

XiFin’s support for H.R. 3164 builds on the company’s broader commitment to breaking down barriers to care and advancing interoperability, with the ultimate goals of enhancing care and improving the patient experience. The company recently joined the Future of Pharmacy Care Coalition to add its voice to others working to improve delivery of clinical care.

About XiFin

XiFin is a healthcare information technology company that empowers organizations to navigate an evolving and increasingly complex healthcare landscape. The XiFin Empower AI RCM ecosystem and trusted data employ active intelligence and automation to reduce manual touches, coordinate workflows, accelerate customer innovation, and improve financial outcomes. Our comprehensive set of solutions — spanning revenue cycle management, clinical workflow enablement, laboratory information systems, and patient engagement — deliver The Power to Do Good® so that healthcare organizations can do more good for more patients. Visit www.XiFin.com or follow XiFin on LinkedIn to learn more, or subscribe to the XiFin blog to learn more.

Contacts

Media Contact:
Peter Collins
908-499-1200
p.collins@togorun.com

XiFin, Inc.

Details
Headquarters: San Diego, CA
CEO: Lâle White
Employees: 900+
Organization: PRI

Release Versions

Contacts

Media Contact:
Peter Collins
908-499-1200
p.collins@togorun.com

Social Media Profiles
More News From XiFin, Inc.

Diagnostic Lab Claim Denials Jumped 40% in 2025, New XiFin Research Report Finds

SAN DIEGO--(BUSINESS WIRE)--Denials of clinical laboratory, molecular diagnostic, and genomics claims rose to 11.2% in 2025 from 8.0% the year before, a 40% jump that erased two years of improvement, according to the recently released 2026 Payor Denial Impact Report from XiFin, Inc., a leader in AI-enabled revenue cycle management (RCM). The report is based on an analysis of more than 30 million claims processed through XiFin’s Empower RCM solution, which serves 11 of the 15 largest laboratorie...

XiFin Launches Fourth Annual Pharmacy Transformation Outlook Survey as Legislative Action Moves to Reshape Pharmacist-Provided Care

SAN DIEGO--(BUSINESS WIRE)--In recognition of American Pharmacists Month, XiFin, Inc., a leading provider of AI-driven revenue cycle management (RCM) solutions and services to more than half of U.S. pharmacies, today opened its fourth annual Pharmacy Transformation Outlook Survey. The research will gather perspectives from pharmacy professionals on reimbursement, specialty pharmacy growth, clinical services, AI adoption, and operational barriers, and will seek to support national advocacy and in...

Frost Radar™ Recognizes XiFin as the Only AI-enabled Ancillary Healthcare RCM Specialist Among Leading North American Providers

SAN DIEGO--(BUSINESS WIRE)--XiFin, Inc., a leader in AI-enabled revenue cycle management (RCM), today announced it has been recognized in the Frost Radar™: Revenue Cycle Management Operations in North America. Frost & Sullivan evaluated more than 100 companies and identified XiFin as one of only 15 providers recognized on its Growth and Innovation indices, and the only company focused exclusively on ancillary healthcare revenue cycle management. Frost & Sullivan estimates the North Amer...
Back to Newsroom